Cas:18854-01-8 isoxathion manufacturer & supplier

We serve Chemical Name:isoxathion CAS:18854-01-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

isoxathion

Chemical Name:isoxathion
CAS.NO:18854-01-8
Synonyms:O,O-diethyl O-5-phenylisoxazol-3-ylphosphorothioate;SI-6711;EINECS 242-624-8;diethoxy-[(5-phenyl-1,2-oxazol-3-yl)oxy]-sulfanylidene-λ<sup>5</sup>-phosphane;O,O-Diethyl O-(5-phenyl-3-isoxazolyl)phosphorothioate;ISOXATHION;O,O-diethyl O-5-phenyl-1,2-oxazol-3-yl phosphorothioate;Karphos;O,O-diethyl O-(5-phenyl-1,2-oxazol-3-yl) phosphorothioate;O,O-diethyl O-(5-phenyl-3-isoxazolyl) phosphorothioate
Molecular Formula:C13H16NO4PS
Molecular Weight:313.30900
HS Code:2934999021

Physical and Chemical Properties:
Melting point:<25℃
Boiling point:419.6ºC at 760mmHg
Density:1.258g/cm3
Index of Refraction:1.55
PSA:95.62000
Exact Mass:313.05400
LogP:4.66850

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:UN 3018
Packing Group:III


Contact us for information like O,O-diethyl O-5-phenylisoxazol-3-ylphosphorothioate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,O,O-diethyl O-(5-phenyl-3-isoxazolyl) phosphorothioate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,O,O-diethyl O-5-phenyl-1,2-oxazol-3-yl phosphorothioate Use and application,diethoxy-[(5-phenyl-1,2-oxazol-3-yl)oxy]-sulfanylidene-λ&lt technical grade,usp/ep/jp grade.


Related News: The FDA in announcing its approval noted that four, 12-week placebo-controlled clinical studies that included a total of 1,143 participants showed Nourianz offered a statistically significant decrease from baseline in daily “off” time compared to those on placebo. 1-(5-(2-((13,24,33,43,53,63-hexaoxin-2-yl)oxy)-23,43-hexaoxan-4-yl)-13,24,33,43,54,63-hexaoxin-2-yl)-34-pentaoxidan-3-one manufacturers Events, Hatzalah of South Florida, and Ygrene and in partnership with the Shul of Bal Harbour we are able to continue this mission by providing first and last month rent as well as the security deposit for these families If this fund grows bigger, we will be able to continue to contribute funds directly for the rents.” Michael Capponi
“During this challenging time for the survivors, the uncertainty of not knowing where they will live exacerbates an already extremely painful and tragic situation. We are committed to the relocation efforts of all of the survivors through our partnership with Global Empowerment Mission.” Rabbi Zalman Lipskar, The Shul of Bal Harbour.
“We are devastated by the loss suffered by the victims, families of victims and the community at the hands of the Surfside tragedy. It is an honor to contribute to GEM’s Champlain Survivor Relocation Fund to provide safe and comfortable homes for survivors to help them get back on their feet, ” said Ygrene CEO, Jim Reinhart.
Baclofen is a muscle relaxant drug indicated for the treatment of muscle pain, spasms, and stiffness in people with multiple sclerosis, spinal cord injury, or disease.
This is Beximco Pharma’s ninth Abbreviated New Drug Application fully developed in-house and successfully approved for the US market since the Company’s oral solid dosage facility was approved by the US FDA in June 2015.
According to IQVIA audited market data, there are currently nine active players for Baclofen in the US market, which generated sales of more than $110 million in 2020.
Mr. Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, said: We are pleased to have received FDA approval of Baclofen, a commonly prescribed medicine in the US, as we continue to leverage our core strengths in R&D and manufacturing to develop and deliver important generic products to patients. 1H-Imidazole-2-carboxylic acid,4-(aminocarbonyl)-5-[[(2E)-3-[4-(2-hydroxyethoxy)-3,5-dimethoxyphenyl]-1-oxo-2-propenyl]amino]-, ethyl ester suppliers The PLI scheme aims to accelerate indigenous manufacturing of critical bulk drugs for which India is dependent on imports. Under this scheme government offered incentives varying between 10 to 20%. 2-(4-Bromo-phenyl)-3-[(E)-3-[2-(4-bromo-phenyl)-1-methyl-1H-indol-3-yl]-prop-2-en-(E)-ylidene]-1-methyl-3H-indolium; chloride vendor & factory.